Skip to main navigation
Skip to main content
Skip to Footer
Google Tag Manager
UK
Novartis Site Directory
Our Work
Clinical Trials
Disease Areas
Novartis in the UK
Partnerships
Grants and sponsorships
About Us
Who We Are
Patient group partnership
Corporate Responsibility
Patients & Caregivers
Contact Us
News
UK News Archive
Stories
Novartis UK Press Office
Careers
Our People and Culture
Future Talent Programme
Career Search
Search
UK News Archive
The UK News Archive contains resources intended for journalists only.
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Media Releases
Stories
Filter By
2021
February
Media Release
/
Feb 26, 2021
Novartis’ Kisqali® (ribociclib) receives NICE recommendation for routine funding as second-line treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer
Read More
Media Release
/
Feb 17, 2021
Maintain COVID-19 collaborations to secure UK’s life sciences lead, recommends new report
Read More
Media Release
/
Feb 12, 2021
Novartis signs initial agreement to provide manufacturing capacity for Pfizer-BioNTech COVID-19 vaccine
Read More
Media Release
/
Feb 03, 2021
NICE issues final guidance recommending Novartis’ novel eye treatment Beovu® (brolucizumab) as an option for wet age-related macular degeneration
Read More
January
Media Release
/
Jan 29, 2021
Novartis receives positive CHMP opinion for Kesimpta® (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis with active disease
Read More
Story
/
Jan 29, 2021
Novartis UK awarded Top Employer status for eighth consecutive year
Read More
Media Release
/
Jan 25, 2021
Novartis UK Estradot supplies statement
Read More
2020
December
Media Release
/
Dec 11, 2020
Aimovig® (erenumab) NICE Final Appraisal Document (FAD) publication – Novartis UK media statement
Read More
November
Story
/
Nov 17, 2020
Novartis walks-the-talk with the Red Shoe Movement
Read More
October
Media Release
/
Oct 15, 2020
Novartis’ Mayzent®▼ (siponimod) becomes the first oral treatment recommended by NICE and SMC for adults living with secondary progressive multiple sclerosis (SPMS) with active disease
Read More
Search Results Navigation
Current page
1
of 4
Page
2
of 4
Page
3
of 4
Page
4
of 4
Next page
next ›
Last page
last »
Related Links
General Privacy Notice for Suppliers
General Privacy Notice for Business Partners
St George's University Hospitals NHS Foundation Trust
ITP Patient Resources
You are here
Home
›
News